Corporate Information
Code of Conduct
PT Mitsubishi Tanabe Pharma Indonesia Code of Conduct sets forth the basic stance on and specific policies in respect of corporate and individual behavior in line with our Corporate Behavior Charter and Declaration of Compliance toward realization of the company’s Philosophy and Vision. All employees of PT Mitsubishi Tanabe Pharma Indonesia are required to understand and comply with this Code and with all other rules and policies of the company.
Principles for Business Activities.
1. CREATION OF PHARMACEUTICALS
“Being the first to deliver unique value”
There is nothing more rewarding than to see patients and their family members and friends smiling after successful treatment. Constantly mindful that “everything we do is for the patients and their families who support them”, we strive to clearly distinctive and novel value by providing original and visionary pharmaceuticals in an effort to become a “company that works with a sense of urgency and is the first to deliver unique value”, thereby opening up the future for both patients and the field of medicine as a whole.“Our mission going forward”
There are still many diseases that cannot be treated adequately through existing therapies and large numbers of sufferers who have limited access to medicine. Hence, it is our duty to deliver innovative new drugs, by the result of research and development of MTPC Global, to those who are eagerly awaiting medicine. Meanwhile, as ever-increasing healthcare expenditure become a major issue in the global community, it is also our mission to contribute to curbing such expenditure and other social costs.Beyond merely easing the symptoms of disease, we seek to relieve patients and their families of mental stress and to provide patients with enjoyment and satisfaction in their lives, a sense of security, and opportunities to continue in, or reintegrate into, society. We believe that pursuing innovations in this way will help our society to prosper and the sustainability of our society.“Maximization of product/pipeline value”
The overall value of medicine is determined by taking into account such aspects as: pharmaceutical efficacy and safety; reliability; usability; and drug information, including information on dosage and administration. From the initial stages of research and development, conducted by MTPC Global, we apply approaches based on medical science to maximize the clinical value of pharmaceuticals by understanding medical needs, conducting medical and pharmacological evaluation, and working to improve cost competitiveness. In the later stages of drug development, we conduct clinical trials, giving consideration to each compound’s unique characteristics. After launch, we continue to monitor for adverse events and drug reactions and conduct clinical research to collect treatment and other information on drugs, thereby accumulating data on their efficacy and safety. Through such initiatives, we maximize the full potential of each type of medicine from an early stage.“The art of drug development”
For a new compound to be launched as medicine, a broad range of research and development activity is required. With every single product, we strive to establish: robust and significant manufacturing technologies, including manufacturing processes, to efficiently produce drug substances with stable quality, drug ingredient mixtures, and formulation designs, to ensure that active ingredients are delivered to therapeutic targets in the body; highly productive manufacturing methods and technologies to scale up such manufacturing; packaging that helps to further enhance the quality of therapies; and appropriate quality evaluation. Our goal is to deliver high-efficiency, low-cost, and high-quality “medicine” to patients. By combining these proven technologies with new materials, devices, IT, and other technologies, we also seek to develop medicine that offers greater convenience.
2. LEGAL REQUIREMENTS AND REGULATIONS
3. SAFETY
We strive to minimize the possibility of health hazards resulting from adverse reactions by reducing the safety risks of our pharmaceuticals. In order for patients to be able to consult physicians for treatment using our pharmaceuticals with peace of mind, we collect and analyze treatment information worldwide on a daily basis during clinical trials and post-marketing surveys, whether the pharmaceuticals in question are in-house or co-developed. Our goal is to provide healthcare professionals with the timely and reliable feedback that they need to appropriately determine a balance between the benefits and risks of a particular pharmaceutical in the treatment of each and every patient.
4. QUALITY ASSURANCE
It is absolutely essential to assure the quality, efficacy, and safety of “medicine” throughout the product lifecycle, from research and development through manufacturing and post-marketing activities. In accordance with the applicable laws, regulations, and public standards of each country in which we operate, we establish and continuously improve systems for ensuring and monitoring compliance with GxP and other guidelines so that we can maintain and operate an effective quality management system that assures the reliability of data and the quality of our pharmaceuticals. We disclose reliable information in a timely and accurate manner.
5. SUPPLY CHAIN
In order to safely deliver to patients pharmaceuticals that both healthcare professionals and patients can use with peace of mind, we strive to assure product quality and reduce costs at every stage of our supply chain, while concurrently building a system for the stable supply of quality pharmaceuticals through constant efforts to develop technologies and improve the relevant systems. We also improve our preparedness to take prompt and appropriate action, even in the event of unforeseen circumstances, by reinforcing the functioning of our entire supply chain and facilitating cooperation among concerned parties.
6. PRODUCT AND MEDICAL INFORMATION
In every country where we market our pharmaceuticals, with pride and a sense of mission as an organization involved in the creation of “medicine” that has significant influence on people’s lives, in accordance with the applicable laws, regulations and trade norms, we provide information to ensure the proper use of our pharmaceuticals as well as important product information for patients and the medical fraternity. While monitoring healthcare conditions and ever-changing patient needs in each country and region, we utilize appropriate measures to provide, collect, and communicate pharmaceutical information, both accurately and in a timely manner. We also provide information as a part of our effort to contribute to regional healthcare in collaboration with healthcare professionals and governments.
7. MANAGEMENT AND UTILIZATION OF INTELLECTUAL PROPERTIES
We create, protect, and put to effective use our globally competitive intellectual properties related to pharmaceuticals, which serve as the basis for our development of innovative pharmaceuticals and proper provision of opportunities for patients to receive healthcare. We pursue intellectual property strategies, which are integrated with our management and research and development strategies in order to establish our rights in a timely manner. PT Mitsubishi Tanabe Pharma Indonesia manages all intellectual property rights held by the Mitsubishi Tanabe Pharma Group in an integrated manner and advances their optimal utilization and protection in order to contribute to enhancement of our corporate value by protecting, licensing, and otherwise utilizing our own pharmaceuticals and business activities.
8. OUR EMPLOYEES
To create innovative new drugs it is vital that employees constantly take on challenges for advancement without fear of failure, and that the organization and corporate culture is geared toward utilizing such talented individuals. With this in mind, we remain flexible in administering our organization so that we can closely connect management decisions with the challenges taken on by employees and produce good results through timely decision-making and actions. We always assign the right people to the right positions by fully acknowledging the importance of different values and suggestions of novel ideas from our diverse employees. In seeking to develop new drugs for which there is a high social need and to maximize their value, we focus on developing professional expertise in each aspect of our value chain, including research, development, production, and sales, and in the corporate functions that underpin them. Toward the goal of creating new value, we constantly seek synergy and cooperation both within and outside of the company in order to establish or expand networks. We promote work environments in which all individuals can find great satisfaction in their work while enjoying good health so that they can maximize their abilities.
9. INFORMATION MANAGEMENT/SECURITY
Recognizing that information represents important management resources and assets, we systematically and efficiently manage and use our information assets according to their nature and significance. We have established and operate appropriate management systems and guidelines for maintenance and enhancement of information security effectiveness. We also implement systematic, personnel-related, physical, and technical safety management measures to ensure information security.
10. DISCLOSURE
We disclose information on our business activities that is reliable and useful for societies and stakeholders in a timely and appropriate manner. When disclosing such information we do so accurately, promptly, proactively and with integrity, taking due care not to infringe copyrights, privacy or other rights, so that every stakeholder can be given fair access to the information disclosed. We also disclose information on our clinical trials in a timely and appropriate manner and in accordance with the laws, regulations, guidelines and trade norms in each country and region.
11. ENVIRONMENT AND SAFETY
In conformity with the overriding principle that safety is paramount, we strive to prevent disasters occurring at workplaces and to implement adequate precautions and preparations against all contingencies, including occupational accidents and disasters. We also take continuing steps to reduce the impact of our corporate activities on the natural environment and we are fully committed to community environmental conservation activities.
12. RESPECT FOR HUMAN RIGHTS
We support the protection of human rights. We also support the elimination of any and all forms of forced labor and the abolition of child labor. We promote creation of healthy workplace environments in which everyone respects each other’s personality and human rights, feels free to speak openly about any matter and maintains good personal relationships. Furthermore, we do not tolerate any act that could infringe fundamental human rights or devalue individual abilities, including cases of discrimination and forms of harassment. We at PT Mitsubishi Tanabe Pharma Indonesia shall not treat our employees in a discriminatory manner on the basis of ethnicity, gender, religion, or other grounds.
13. ASSURANCE OF FAIR BUSINESS
We always pay attention to any discrepancies between social norms and the company’s positions and never engage in any conduct that would go against such norms. Whilst strengthening corporate governance and promoting compliance, we check our internal control systems as necessary and make any necessary improvements to increase their effectiveness in order to prevent risks from arising.
In strict observance of the competition laws and other relevant regulations in each country, we engage in fair and free competition in the marketplace. We do not abuse our position in business transactions in order to impose unreasonable requests, rather, we build relationships of mutual trust through fair transactions. We maintain sound and proper relationships in transactions associated with business activities on the basis of accurate understanding of anti-corruption and bribery laws and regulations. We put the capital, goods and other assets of the company to efficient and proper use in order to achieve efficient business management. We are committed to maintaining sound and proper relationships with political bodies and government agencies.
Avoiding conflicts of interest all decisions are based on objective considerations of facts which are free of any conflicts of interest. Business decisions are based solely on the best interest of the Company, without regard to personal, family, or other outside considerations.
14. ANTI-BRIBERY AND CORRUPTION
We commit to avoid corruption and bribery. It is PT Mitsubishi Tanabe Pharma Indonesia’s policy to conduct all business in an honest and ethical manner. PT Mitsubishi Tanabe Pharma Indonesia takes a zero-tolerance approach to Bribery and Corruption and is committed to acting professionally, fairly and with integrity in all of its business dealings and relationships, and implementing and enforcing effective systems to counter Bribery and Corruption. This commitment is set out by an Anti-Bribery and Corruption policy which is established by management and effectively implemented on December 2017, in accordance with the legislation applied in Indonesia about bribery and corruption and Global Anti-Bribery and Corruption Policy Guidelines (for Indonesia) by Mitsubishi Tanabe Pharma Corporation.
15. RESPONSIBILITIES AS A CORPORATE CITIZEN
In order to fulfill our social responsibilities as a good corporate citizen, we respect the cultures and customs of the countries and regions in which we operate, conduct our business activities giving due consideration to such cultures and customs and promote worthy social contribution activities. We also provide individual employees with workplace environments that make it easy for them to independently participate in volunteer activities.